Istiratumab, CAS 1509928-04-4

Product Description: Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87. /[2]Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. /[3]Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832.

CAS Number: 1509928-04-4

Molecular Weight: N/A

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: EGFR;IGF-1R

• Artikelnummer: MEXHY-P99672-0
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99672-0
• Verpackungseinheit: Get quote
• Mengeneinheit: STK
• Konjugat: Unconjugated